BCM
AUTL

Bayesian Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Bayesian Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-65,000
Closed -$153K – 605
2024
Q4 		$153K Buy
65,000
+41,600
+178% +$141K 0.02% 589
2024
Q3 		$84.9K Sell
23,400
-16,000
-41% -$63.8K 0.01% 609
2024
Q2 		$137K Buy
39,400
+23,800
+153% +$103K 0.02% 639
2024
Q1 		$99.5K Buy
+15,600
New +$97.3K 0.01% 713

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bayesian Capital Management's AUTL Position: Q1 2025 in Review

Bayesian Capital Management sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 65,000 shares — an estimated $153K sold.

Bayesian Capital Management first reported a position in AUTL in Q1 2024 and held it in 4 quarters. The position peaked at $153K in Q4 2024. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

  • Bayesian Capital Management reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 65,000 Autolus Therapeutics shares in Q1 2025, an estimated $153K.
  • Bayesian Capital Management first reported a position in Autolus Therapeutics in Q1 2024 and held it in 4 quarters.
  • Bayesian Capital Management's Autolus Therapeutics position peaked at $153K in Q4 2024.
  • 95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.